GET THE PREMIUM SUBSCRIPTION FREE FOR 14 DAYS!

BioLineRx Ltd. Company Profile

2 HaMa’ayan Street

Modi’in 7177871

972 8 642 9100

www.biolinerx.com

Industry: Biotechnology

Sector: Healthcare

BioLineRx Ltd.

Description

BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs. Its development pipeline consists of three primary clinical-stage therapeutic candidates, which include BL-8040, a novel peptide for the treatment of multiple cancer and hematological indications; BL-7010, a novel co-polymer for the treatment of celiac disease and gluten sensitivity; and BL-5010, a customized, proprietary, pen-like applicator containing a novel, acidic, aqueous solution as a medical device for the non-surgical removal of benign skin lesions. The company’s other therapeutic candidates comprise BL-8020, an orally available treatment for the hepatitis C virus, and other viral indications; and BL-1040, a novel, resorbable polymer solution for use in the prevention of ventricular remodeling that may occur in patients who have suffered an acute myocardial infarction. It also has a preclinical stage therapeutic candidate, BL-9020, which is a novel monoclonal antibody treatment designed to prevent immune-mediated destruction of insulin-producing beta cells in the pancreas. The company has strategic collaborations with Novartis Pharma AG; Merck; The University of Texas MD Anderson Cancer Center to investigate the combination of BL-8040 with Keytruda (pembrolizumab) in pancreatic cancer; and Genentech, Inc. to support various Phase Ib studies investigating the company’s BL-8040 in combination with the Genentech’s Atezolizumab in multiple cancer indications. BioLineRx Ltd. was founded in 2003 and is headquartered in Modi’in, Israel.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE